Nebula Research & Development LLC increased its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 35.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,845 shares of the company's stock after acquiring an additional 13,484 shares during the quarter. Nebula Research & Development LLC's holdings in Guardant Health were worth $1,584,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Guardant Health during the fourth quarter valued at about $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman & Baird LLC acquired a new stake in Guardant Health in the fourth quarter valued at approximately $58,000. NewEdge Advisors LLC boosted its stake in Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Guardant Health in the fourth quarter worth $80,000. 92.60% of the stock is owned by hedge funds and other institutional investors.
Guardant Health Price Performance
GH stock traded up $1.01 during mid-day trading on Thursday, reaching $48.24. 2,624,043 shares of the company's stock were exchanged, compared to its average volume of 2,158,496. Guardant Health, Inc. has a 12-month low of $17.85 and a 12-month high of $52.99. The stock's 50 day moving average is $43.48 and its 200 day moving average is $37.75. The company has a market cap of $5.95 billion, a price-to-earnings ratio of -13.56 and a beta of 1.45.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently commented on the stock. Mizuho initiated coverage on shares of Guardant Health in a research note on Thursday, April 10th. They issued an "outperform" rating and a $55.00 target price for the company. Scotiabank boosted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Monday, February 24th. Raymond James reissued an "outperform" rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Stephens reaffirmed an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Finally, Barclays increased their price objective on Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday. Twenty-one investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $51.41.
Check Out Our Latest Stock Analysis on Guardant Health
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Read More
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
